不同浓度吡柔比星膀胱灌注预防非肌层浸润性膀胱癌复发的有效性及安全性比较

邓新军; 李正明; 李颂; 李刚; 黄文胜; 施国强

doi:10.13201/j.issn.1001-1420.2017.03.016

不同浓度吡柔比星膀胱灌注预防非肌层浸润性膀胱癌复发的有效性及安全性比较

- 广州市红十字会医院, 暨南大学医学院附属广州红十字会医院泌尿外科, （广州, 510220）

详细信息

通讯作者: 邓新军, E-mail:dengxinjun30@163.com

中图分类号: R737.14

收稿日期: 2016-03-11

Effectiveness and safety of different doses of pirarubicin on preventing non-muscle invasive bladder cancer recurrence by intravesical instillation

- Department of Urology, Guangzhou Red Cross Hospital, Medical College of Jinan University, Guangzhou, 510220, China

More Information

Corresponding author: DENG Xinjun, E-mail: dengxinjun30@163.com

Received Date: 11 March 2016

摘要

摘要: 目的:探讨不同剂量吡柔比星膀胱灌注预防非肌层浸润性膀胱癌的有效性和安全性。方法:将216例非肌层浸润性膀胱癌患者随机分成三组, 行经尿道膀胱肿瘤电切术 (TURBt术) 后分别应用吡柔比星30 mg (90例) 、40 mg (64例) 、50 mg (62例) 加入0.9%氯化钠溶液30 ml中膀胱灌注化疗, 比较各组患者2年内膀胱肿瘤复发情况及灌注后不良反应发生情况。结果:50 mg组 (14.5%) 的2年复发率较30 mg组 (41.1%) 和40 mg组 (32.8%) 明显降低 (P<0.05), 且50 mg组平均复发时间为 (14.30±3.10) 个月, 较30 mg组 (8.30±2.80) 个月和40 mg组 (7.50±2.60) 个月明显延长 (P<0.01);各组均有发生膀胱刺激征患者, 50 mg组发生率 (40.3%) 明显高于30 mg组 (21.1%) 和40 mg组 (18.8%) (P<0.01), 但经对症处理后症状均可缓解。结论:非肌层浸润性膀胱癌患者行TURBt术后使用吡柔比星50 mg膀胱灌注治疗更能有效抑制膀胱肿瘤复发, 且不良反应可控。
- 非肌层浸润性膀胱癌 /
- 吡柔比星 /
- 复发 /
- 膀胱灌注
Abstract: Objective:To evaluate the effectiveness and safety of different doses of pirarubicin on preventing non-muscle invasive bladder cancer recurrence by intravesical instillation.Method:Two hundred and sixteen patients with non-muscle invasive bladder cancer were randomly divided into three groups.They were treated with different doses of pirarubicin by intravesical instillation after TURBt:30 mg (n=90), 40 mg (n=64) and 50 mg (n=62) dissolved in 30 ml of physiological saline.Then two-year recurrence rate and the adverse reaction after bladder perfusion therapy were compared.Result:The two-year recurrence rate in 50 mg group (14.5%) was lower than those in 30 mg group (41.1%) and 40 mg group (32.8%) (P<0.05), and the mean recurrence time of 50 mg group (14.30±3.10) months was longer than those of 30 mg group (8.30±2.80) months and 40 mg group (7.50±2.60) months (P<0.01).The irritative symptoms were found in every group, but a higher rate in 50 mg group (40.3%) than those in 30 mg group (21.1%) and 40 mg group (18.8%) (P<0.01) was found.All of these adverse reactions were alleviated after heteropathy.Conclusion:We recommend using pirarubicin at the dose of 50 mg for preventing non-muscle invasive bladder cancer recurrence by intravesical instillation.
- non-muscle invasive bladder cancer /
- pirarubicin /
- recurrence /
- intravesical instillation

HTML全文

参考文献(10)

[1]	那彦群, 叶章群, 孙颖浩, 等.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社, 2014:20-60.
[2]	李鹏程, 李飞, 宋亚辉, 等.吡柔比星对膀胱癌EJ细胞增殖及Livin和Caspase-3表达的影响[J].医学研究生学报, 2015, 28 (3):255-259.
[3]	Kuroda M, Niijima T, Kotake T, et al.Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG):a randomized trial of intravesical epirubicin at dose of 20 mg/40ml, 30mg/40ml, 40mg/40ml[J].Eur Urol, 2004, 45 (5):600-605.
[4]	邵勇, 祝青国.吡柔比星膀胱灌注预防膀胱癌术后复发的临床观察[J].中国肿瘤杂志, 2007, 16 (9):748-750.
[5]	孙晓文.非肌层浸润膀胱尿路上皮癌诊治中存在的问题及思考[J/CD].中华临床医师杂志 (电子版), 2015, 9 (2):185-187.
[6]	Zheng S E, Xiong S, Lin F, et al.Pirarubicin inhibits multidrugresistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest[J].Acta Pharmacol Sin, 2012, 33 (6):832-838.
[7]	Bhattacharya A, Li Y, Shi Y, et al.Enhanced inhibition of urinary bladder cancer growth and muscle invasion by ally lisothiocyanate and celecoxib in combination[J].Carcinogenesis, 2013, 34 (11):2593-2599.
[8]	冉俊武, 吕军, 王尉, 等.荧光原位杂交和核基质蛋白22联合检测在膀胱癌诊断中的应用[J].实用医学杂志, 2014, 30 (7):1073-1076.
[9]	袁红纲, 龙兵, 董自强, 等.吡柔比星联合顺铂膀胱灌注预防膀胱癌复发的诊治体会[J].现代肿瘤医学, 2015, 23 (6):835-836.
[10]	Wu P, Zhu G, Wei D, et al.Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma:A systematic review and meta-analysis[J].J BUON, 2015, 20 (5):1229-1238.